Dispatch Bio’s virus therapy DV-10 enters phase 1.
ApexOnco Front Page
Recent articles
The company discontinues the Lag3 project in lung cancer.
The company takes a PD-L1 x VEGF asset into phase 3.
A new phase 3, Manifest-3, will start in April to support US filing.
Intismeran autogene’s Interpath-001 trial reads out this year.
New first-in-human study initiations feature yet more in vivo Car assets.
The biotech licenses a China-developed anti-B7-H3 ADC.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
